N/A N=4 Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Clofarabine Bone Marrow Cytoreduction
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants
Phase 3 N=97 Prospective Study of Patients With Thrombocytopenia Following HSCT
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Phase 2 N=47 Alemtuzumab to Treat Severe Aplastic Anemia
Severe Aplastic Anemia, Refractory · Severe Aplastic Anemia, Relapse
Primary: Number of Participants With Hematological Response at 6 Months — 0; 18 Participants
Phase 2 N=54 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Aplastic Anemia
Primary: Participants no Longer Meeting Criteria for Severe Aplastic Anemia. — 18; 17; 9; 9 participants
Phase 2 N=80 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Phase 2 N=35 Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia
Aplastic Anemia
Primary: Number of Participants With Response to Rabbit Antithymocyte Globulin (Thymoglobuline) — 1; 11; 18; 3 Participants
Phase 2 N=20 Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Aplastic Anemia
Primary: Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months — 9 participants
N/A N=11 TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Phase 3 N=98 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Primary Immune Deficiency Disorder · Hematopoietic Stem Cell Transplantation
Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95
Phase 2 N=22 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Aplastic Anemia · Neutropenia · Pancytopenia
Primary: Blood Counts and Adverse Event Profile After 6 Months of Treatment. — 4; 5; 12 participants
Phase 2 N=48 Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Myelodysplastic Syndrome · Aplastic Anemia
Primary: Overall Response — 8; 8; 4 participants
Phase 2 N=30 Sirolimus for Autoimmune Disease of Blood Cells
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Phase 2 N=2 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Bone Marrow Failure Syndromes · Immunodeficiencies · Immune Dysregulation Syndromes
Primary: Number of Participants With Engraftment — 2 Participants
N/A N=1,347 A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
Breast Cancer · Non-Small Cell Lung Cancer · Ovarian Cancer
Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants
N/A N=9 Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
Aplastic Anemia
Primary: Number of Patients With Engraftment Response — 9 Participants
Phase 2 N=44 Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Neural Tube Defects · Anemia · Leukemia, Myeloid
Primary: Full Donor Chimerism (FDC) — 6 Participants
Phase 2 N=11 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Phase 2 N=34 Eltrombopag for Moderate Aplastic Anemia
Moderate Aplastic Anemia · Unilineage Bone Marrow Failure Disorders
Primary: Proportion of Drug Responders — 17 Participants
Phase 2 N=136 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Immunosuppresion · Thrombocytopenia · Pancytopenia
Primary: Hematologic Response — 38; 20; 3 Participants
Phase 2 N=97 Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Anemia, Aplastic
Primary: Disease-free Survival (DFS) — 6; 3; 9; 4 participants
Phase 2 N=2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Hemoglobinopathies · Sickle Cell Disease · Thalassemia
Primary: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy. — 2 participants
Phase 2 N=31 Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
Fanconi Anemia
Primary: Number of Participants Experiencing Graft Failure — 0; 0; 0 Participants
Phase 2 N=54 Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
Severe Aplastic Anemia
Primary: Overall Hematologic Response Rate by 6 Months — 46.3 Percentage of participants
Phase 2 N=60 CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Advanced Solid Tumor Malignancy
Primary: Type and Number of Adverse Events (AEs) — 24; 37; 62; 143 number of events
Phase 2 N=42 Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
Myelodysplastic Syndrome
Primary: Red Blood Cell Transfusion Independence — 6; 10; 21 participants
Phase 2 N=16 Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
Sickle Cell Disease & Thalassemia
Primary: Safety and Tolerability Will be Measured by Acute NiCord® Infusional Toxicity. — 0; 0; 3; 0 participants
Phase 2 N=2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Sickle Cell Anemia · Severe Aplastic Anemia · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Patients With Neutrophil Engraftment — 2 participants
N/A N=61 Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Phase 2 N=21 High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
GVHD
Primary: Percentage of Participants Who Experience Acute GvHD — 38.46 percentage of participants